314 related articles for article (PubMed ID: 27682852)
21. Follow-up to Age 4 Years of Treatment of Type 1 Retinopathy of Prematurity Intravitreal Bevacizumab Injection versus Laser: Fluorescein Angiographic Findings.
Lepore D; Quinn GE; Molle F; Orazi L; Baldascino A; Ji MH; Sammartino M; Sbaraglia F; Ricci D; Mercuri E
Ophthalmology; 2018 Feb; 125(2):218-226. PubMed ID: 28867130
[TBL] [Abstract][Full Text] [Related]
22. PROGRESSIVE RETINAL DETACHMENT IN INFANTS WITH RETINOPATHY OF PREMATURITY TREATED WITH INTRAVITREAL BEVACIZUMAB OR RANIBIZUMAB.
Yonekawa Y; Wu WC; Nitulescu CE; Chan RVP; Thanos A; Thomas BJ; Todorich B; Drenser KA; Trese MT; Capone A
Retina; 2018 Jun; 38(6):1079-1083. PubMed ID: 28471890
[TBL] [Abstract][Full Text] [Related]
23. Retinal fluorescein angiographic changes following intravitreal anti-VEGF therapy.
Henaine-Berra A; Garcia-Aguirre G; Quiroz-Mercado H; Martinez-Castellanos MA
J AAPOS; 2014 Apr; 18(2):120-3. PubMed ID: 24698606
[TBL] [Abstract][Full Text] [Related]
24. FACTORS ASSOCIATED WITH REACTIVATION AFTER INTRAVITREAL BEVACIZUMAB OR RANIBIZUMAB THERAPY IN INFANTS WITH RETINOPATHY OF PREMATURITY.
Iwahashi C; Utamura S; Kuniyoshi K; Sugioka K; Konishi Y; Wada N; Kusaka S
Retina; 2021 Nov; 41(11):2261-2268. PubMed ID: 33958533
[TBL] [Abstract][Full Text] [Related]
25. Reactivation of retinopathy of prematurity after ranibizumab treatment.
Wong RK; Hubschman S; Tsui I
Retina; 2015 Apr; 35(4):675-80. PubMed ID: 25768252
[TBL] [Abstract][Full Text] [Related]
26. Comparison of clinical outcomes of intravitreal ranibizumab and aflibercept treatment for retinopathy of prematurity.
Sukgen EA; Koçluk Y
Graefes Arch Clin Exp Ophthalmol; 2019 Jan; 257(1):49-55. PubMed ID: 30397793
[TBL] [Abstract][Full Text] [Related]
27. FLUORESCEIN ANGIOGRAPHY EVALUATION OF CHILDREN PREVIOUSLY TREATED WITH ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR MONOTHERAPY FOR RETINOPATHY OF PREMATURITY.
Poslu Karademir F; Vural A; Özbaş M; Demirayak B
Retina; 2024 May; 44(5):901-908. PubMed ID: 38150651
[TBL] [Abstract][Full Text] [Related]
28. SERUM VASCULAR ENDOTHELIAL GROWTH FACTOR AFTER BEVACIZUMAB OR RANIBIZUMAB TREATMENT FOR RETINOPATHY OF PREMATURITY.
Wu WC; Shih CP; Lien R; Wang NK; Chen YP; Chao AN; Chen KJ; Chen TL; Hwang YS; Lai CC
Retina; 2017 Apr; 37(4):694-701. PubMed ID: 27467377
[TBL] [Abstract][Full Text] [Related]
29. Which dose of bevacizumab is more effective for the treatment of aggressive posterior retinopathy of prematurity: lower or higher dose?
Dikci S; Ceylan OM; Demirel S; Yılmaz T
Arq Bras Oftalmol; 2018; 81(1):12-17. PubMed ID: 29538588
[TBL] [Abstract][Full Text] [Related]
30. Ranibizumab or Bevacizumab for Neovascular Age-Related Macular Degeneration According to the Lucentis Compared to Avastin Study Treat-and-Extend Protocol: Two-Year Results.
Berg K; Hadzalic E; Gjertsen I; Forsaa V; Berger LH; Kinge B; Henschien H; Fossen K; Markovic S; Pedersen TR; Sandvik L; Bragadóttir R
Ophthalmology; 2016 Jan; 123(1):51-9. PubMed ID: 26477842
[TBL] [Abstract][Full Text] [Related]
31. Early vitreoretinal surgery on vascularly active stage 4 retinopathy of prematurity through the preoperative intravitreal bevacizumab injection.
Xu Y; Zhang Q; Kang X; Zhu Y; Li J; Chen Y; Zhao P
Acta Ophthalmol; 2013 Jun; 91(4):e304-10. PubMed ID: 23647944
[TBL] [Abstract][Full Text] [Related]
32. Comparison of intravitreal ranibizumab and bevacizumab treatment for retinopathy of prematurity.
Erol MK; Coban DT; Sari ES; Bilgin AB; Dogan B; Ozdemir O; Tunay ZO
Arq Bras Oftalmol; 2015; 78(6):340-3. PubMed ID: 26677033
[TBL] [Abstract][Full Text] [Related]
33. Intravitreal bevacizumab monotherapy for retinopathy of prematurity.
Şahin A; Şahin M; Cingü AK; Çınar Y; Türkcü FM; Yüksel H; Kaya S; Arı Ş; Caça İ
Pediatr Int; 2013 Oct; 55(5):599-603. PubMed ID: 23659781
[TBL] [Abstract][Full Text] [Related]
34. Clinical Management of Recurrent Retinopathy of Prematurity after Intravitreal Bevacizumab Monotherapy.
Mintz-Hittner HA; Geloneck MM; Chuang AZ
Ophthalmology; 2016 Sep; 123(9):1845-55. PubMed ID: 27241619
[TBL] [Abstract][Full Text] [Related]
35. Involution patterns of retinopathy of prematurity after treatment with intravitreal bevacizumab: implications for follow-up.
Isaac M; Tehrani N; Mireskandari K;
Eye (Lond); 2016 Mar; 30(3):333-41. PubMed ID: 26869159
[TBL] [Abstract][Full Text] [Related]
36. Retinopathy of Prematurity Reactivated 28 Months after Injection of Ranibizumab.
Ji MH; Moshfeghi DM; Callaway NF; Bodnar Z; Schachar IH; Amorelli GM; Orazi L; Molle F; Lepore D
Ophthalmol Retina; 2019 Oct; 3(10):913-915. PubMed ID: 31474514
[No Abstract] [Full Text] [Related]
37. Fluorescein angiographic observations of peripheral retinal vessel growth in infants after intravitreal injection of bevacizumab as sole therapy for zone I and posterior zone II retinopathy of prematurity.
Tahija SG; Hersetyati R; Lam GC; Kusaka S; McMenamin PG
Br J Ophthalmol; 2014 Apr; 98(4):507-12. PubMed ID: 24403566
[TBL] [Abstract][Full Text] [Related]
38. Aggressive Posterior Retinopathy of Prematurity Treated with Intravitreal Bevacizumab: Late Period Fluorescein Angiographic Findings.
Perente I; Eris E; Seymen Z; Cevik SG; Bekmez S
Graefes Arch Clin Exp Ophthalmol; 2019 Jun; 257(6):1141-1146. PubMed ID: 30895452
[TBL] [Abstract][Full Text] [Related]
39. The vascularization process after intravitreal ranibizumab injections for aggressive posterior retinopathy of prematurity.
Sukgen EA; Koçluk Y
Arq Bras Oftalmol; 2017; 80(1):30-34. PubMed ID: 28380099
[TBL] [Abstract][Full Text] [Related]
40. Comparison of Vascular Outgrowth Rate and Retinal Vascular Development Border after Intravitreal Injection of Aflibercept or Bevacizumab to Treat Retinopathy of Prematurity.
Vural A; Yıldız Ekinci D
Ophthalmologica; 2020; 243(2):86-93. PubMed ID: 31593948
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
